Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
作者信息
Vermeire S, Louis E, Dewit O, Franchimont D, Moreels T, Ferrante M, Rahier J-F, Van Hootegem Ph, De Vos M, Mana F, Baert F
出版信息
Acta Gastroenterol Belg. 2015 Jan-Mar;78(1):26-9.
PMID:26118575
Abstract
摘要
相似文献
1
Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
Acta Gastroenterol Belg. 2015 Jan-Mar;78(1):26-9.
2
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:27-34. doi: 10.1586/17474124.2015.1091307.
3
Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:5-15. doi: 10.1586/17474124.2015.1091304.
4
An update on biosimilar drugs for inflammatory bowel disease.
Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:1-3. doi: 10.1586/17474124.2015.1091305.
5
The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:17-26. doi: 10.1586/17474124.2015.1091306.
6
A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
Immunotherapy. 2018 Feb;10(2):107-117. doi: 10.2217/imt-2017-0107. Epub 2017 Nov 10.
7
Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Aliment Pharmacol Ther. 2015 Nov;42(10):1158-69. doi: 10.1111/apt.13402. Epub 2015 Sep 13.
8
Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases.
J Crohns Colitis. 2020 Jun 19;14(5):680-685. doi: 10.1093/ecco-jcc/jjz209.
9
The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
Gastrointest Endosc Clin N Am. 2019 Jul;29(3):405-419. doi: 10.1016/j.giec.2019.03.001. Epub 2019 Apr 12.
10
A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.
Inflamm Bowel Dis. 2016 Oct;22(10):2513-26. doi: 10.1097/MIB.0000000000000886.
引用本文的文献
1
Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.
J Mark Access Health Policy. 2017 Apr 28;5(1):1307315. doi: 10.1080/20016689.2017.1307315. eCollection 2017.
Zotero 插件